Slide 1: Zumilokibart (APG777) Asthma Phase 1b Interim Results
Zumilokibart (APG777) Asthma Title text 2 Phase 1b Interim Results January 6, 2026
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements ab
Slide 3: Agenda
Agenda Michael Henderson, MD Introduction Chief Executive Officer Zumilokibart (APG777) Carl Dambkowski, MD Asthma Phase 1b Results Chief Medical Officer Invited KOL: Mario Castro, MD, MPH IL-13 inhibition in asthma University of Kansas School of Medicine Michael Henderson, MD Closing remarks Chief
Slide 4: Introduction
Introduction Michael Henderson, MD Chief Executive Officer
Slide 5: 2026 could be a transformational year for Apogee
2026 could be a Expected Key 2026 Milestones: transformational year for Apogee ✓ Zumilokibart (APG777) Asthma Phase 1b positive data UPDATE: Robust effect on FeNO comparable to DUPIXENT; Q1 sustained FeNO suppression after a single dose for 16 weeks, with continued FeNO suppression through 32 weeks
Slide 6: Zumilokibart (APG777) targets IL-13, the core driver of multiple I&I diseases
Zumilokibart (APG777) targets IL-13, the core driver of multiple I&I diseases Atopic dermatitis • Part A 16-week data demonstrated potentially best-in-class profile • Patients in Part A with comorbid asthma or sinusitis saw improvement based on ACQ-5 and SNOT-22 Expansion indications UPDATE • Asthma
Slide 7: Apogee is entering late-stage development in the two largest I&I markets
Apogee is entering late-stage development in the two largest I&I markets Projected growth for key I&I markets (2023-2030) 20 Clinical PoC for zumilokibart (APG777) +15.6 Projected sales growth (% CAGR, 2023-30) 10 +7.4 +5.6 +4.8 +3.3 0 -4.5 -10 US biologics penetration IBD RA PsO COPD Asthma AD 0% 6
Slide 8: Zumilokibart (APG777) Asthma Phase 1b Interim Results
Zumilokibart (APG777) Asthma Phase 1b Interim Results Carl Dambkowski, MD Chief Medical Officer
Slide 9: Zumilokibart Phase 1b interim data achieved or exceeded trial objectives
ZUMILO KIBART ( APG 777) PHASE 1B Zumilokibart Phase 1b interim data achieved or exceeded trial objectives GOAL GOAL GOAL Confirm safety of zumilokibart Demonstrate activity of Show sustained suppression as monotherapy in an asthma zumilokibart via maximum mean of FeNO supporting every 3- patient po
Slide 10: Zumilokibart Phase 1b was designed to address shortcomings of lebrikizumab asthma trials
ZUMILO KIBART ( APG 777) PHASE 1B Zumilokibart Phase 1b was designed to address shortcomings of lebrikizumab asthma trials Optimized dosing Improved patient selection P < 0.001 2,750 mg Zumilokibart (720mg x1) Lebri ITT 46% Lebri (125mg Q4W) Lebri FeNO ≥50, Lebri asthma dose ≥ 1 exac N.S. Lebri AD d
Slide 11: Zumilokibart Phase 1b in mild-to-moderate asthma patients focused on FeNO
ZUMILO KIBART ( APG 777) PHASE 1B Zumilokibart Phase 1b in mild-to-moderate asthma patients focused on FeNO – a surrogate marker of treatment response in Type 2 asthma Design elements Primary objectives Double-blind, placebo-controlled, • Safety: Confirm safety of zumilokibart as monotherapy in Sing
Slide 12: Baseline characteristics are in line with expectations
ZUMILO KIBART ( APG 777) PHASE 1B Baseline characteristics are in line with expectations Placebo Zumilokibart N=5 N=14 Age in years, mean (SD) 51.2 (8.2) 42.1 (13.3) Female 40.0% 42.9% White 80.0% 92.9% Weight in kg, mean (SD) 92.5 (16.2) 81.0 (12.8) Patients on daily ICS ± LABA 100.0% 78.6% Blood e
Slide 13: Zumilokibart was well-tolerated in mild-to-moderate asthma patients
ZUMILO KIBART ( APG 777) PHASE 1B Zumilokibart was well-tolerated in mild-to-moderate asthma patients Placebo Zumilokibart n (%) N=5 N=14 ≥1 TEAE 4 (80.0%) 7 (50.0%) ≥1 serious TEAE 0 0 ≥1 Grade 3 or 4 TEAE 0 0 ≥1 drug-related TEAE 0 0 ≥1 drug-related serious TEAE 0 0 ≥1 drug-related Grade 3 or 4 TE
Slide 14: Single dose of zumilokibart led to durable FeNO suppression
ZUMILO KIBART ( APG 777) PHASE 1B Single dose of zumilokibart led to durable FeNO suppression Zumilokibart 720 mg Complete follow-up (N=14)1 Incomplete follow-up Placebo Complete follow-up (N=5) Incomplete follow-up2 FeNO mean absolute change from baseline FeNO mean percent change from baseline 22%
Slide 15: Single dose of zumilokibart achieved competitive FeNO reduction
ZUMILO KIBART ( APG 777) PHASE 1B Single dose of zumilokibart achieved competitive FeNO reduction FeNO mean absolute change from baseline at 12 weeks (ppb) BL FeNO (ppb)1 34 36 63 53 32 41 64 32 61 31 40 67 0 -10 -10 FeNO, mean change from -11 -11 -16 -16 -16 -20 baseline (ppb) -19 -30 -30 -32 -40 -
Slide 16: Zumilokibart achieved or exceeded trial objectives, derisking path forward in asthma
ZUMILO KIBART ( APG 777) PHASE 1B Zumilokibart achieved or exceeded trial objectives, derisking path forward in asthma and demonstrating expansion potential for zumilokibart Primary trial objectives Supplemental endpoints Well tolerated with no Grade 3 or 4 AEs, no SAEs, no conjunctivitis and no ISR
Slide 17: Closing remarks
Closing remarks Michael Henderson, MD Chief Executive Officer
Slide 18: Zumilokibart has potential to become a leading therapy in the $15B+ future asthma biologics market
ZUMILO KIBART ( APG 777) Zumilokibart has potential to become a leading therapy in the $15B+ future asthma biologics market $16 • Global asthma biologics market is $14 forecasted to grow to ~$16B by 2028 $12 • DUPIXENT has leading market share (~30%) among asthma biologics: $10 • Only biologic appro
Slide 19: Zumilokibart has the potential to be a differentiated drug for Type 2 inflammatory conditions
ZUMILO KIBART ( APG 777) Zumilokibart has the potential to be a differentiated drug for Type 2 inflammatory conditions including AD and asthma 70 Reduction in asthma exacerbations 60 Zumilokibart Clinical PoC in both asthma and AD (labeled population) 50 40 Labeled for AD and asthma Labeled for asth
Slide 20: Multiple potential blockbuster expansions in dermatology, respiratory and GI
ZUMILO KIBART ( APG 777) Multiple potential blockbuster expansions in dermatology, respiratory and GI with prioritization to start ASPIRE asthma trial Atopic dermatitis Multiple potential expansions in respiratory and GI • Asthma • Bullous Pemphigoid • Allergic Rhinitis (perennial) • Chronic Spontan
Slide 21: 2026 could be a transformational year for Apogee
2026 could be a Well-capitalized to deliver key milestones with $913M in cash1 and runway into 2H 2028 transformational Expanding zumilokibart beyond atopic dermatitis year for Apogee ✓• Q1 2026: Asthma Phase 1b positive data Establishing potential best-in-class dosing for zumilokibart in future $50
Slide 22: Apogee /ˈapəjē/ noun
Apogee /ˈapəjē/ noun The highest point in the development of something; a climax or culmination